Stockreport

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Tulisokibart is now being evaluated in two Phase 3 studies in ulcerative colitis and Crohn’s disease12-week data from the Phase 2 ARTEMIS-UC trial recently published in [Read more]